Latest News and Press Releases

BO-112 demonstrates potential as best-in-class therapy to overcome anti-PD1 resistance in melanoma patients whose disease has progressed on prior anti-PD-1 treatment Primary endpoint met with a 30%...

MADRID, Spain, March 15, 2022 (GLOBE NEWSWIRE) -- Highlight Therapeutics, ("Highlight"), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, today announced an...

Intratumoral co-injection of BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy Pre-clinical study data follow publication of positive Phase 2 results of BO-112 +...

Highlight Therapeutics gibt auf der SITC positive vorläufige Ergebnisse der Phase-IIb-Studie zu BO-112 + Anti-PD1 bei Melanompatienten mit bestätigter Progression nach Anti-PD-1-Erstlinienbehandlung...

Highlight Therapeutics annonce les résultats préliminaires positifs de l'étude de phase 2b sur le BO-112 + anti-PD1 chez des patients atteints de mélanome dont la maladie avait progressé avec...

Highlight Therapeutics announces positive preliminary results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at SITC Breakthrough cancer treatment shows...

BO-112 demonstrates potential as best-in-class therapy to overcome anti-PD1 resistance in melanoma patients whose disease has progressed on prior anti-PD1 treatment Primary endpoint met with a...

Highlight Therapeutics to present data from Phase 2 immunotherapy studies of liver metastases and melanoma data at AACR Virtual Annual Meeting 2021 MADRID, Spain, April 14, 2021 (GLOBE NEWSWIRE) --...

Highlight Therapeutics and Pivotal work together on Melanoma therapy andlaunch a Phase IIa trial to examine BO-112 efficacy and safety Trial will examine administration of Highlight's BO-112 in...

Highlight Therapeutics announces first patient dosed in Phase IIa study in liver metastasis Second collaboration with MSD to evaluate combination of BO-112 and KEYTRUDA® New research studies may...